Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)High Risk Acute Myeloid Leukemia(AML)Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Thiotepa ;busulfan;fludarabine
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT06869265
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation
- Conditions
- Acute Lymphoblastic Leukemia ALLAcute Myeloid Leukemia (AML)
- Interventions
- Biological: HSCT donor leukemia-specific cytotoxic T-cells
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 15
- Registration Number
- NCT06865352
- Locations
- 🇮🇹
Fondazione IRCCS Policlinico San Matteo, SC Ematologia 2 - Oncoematologia Pediatrica, Pavia, Italy
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 600
- Registration Number
- NCT06852222
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Conditions
- Relapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)Relapsed/Refractory AMLRelapsed Myelodysplastic SyndromesRefractory Myelodysplastic SyndromesRelapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Auron Therapeutics, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT06846606
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- AMLAcute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- CERo Therapeutics Holdings, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06834282
- Locations
- 🇺🇸
Sarah Cannon Research Insitute, Nashville, Tennessee, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT06811233
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
- Conditions
- Acute Myeloid Leukemia, Relapsed, AdultAcute Myeloid Leukemia RefractoryChronic Myeloid Leukemia - Accelerated PhaseMyelodysplastic Syndromes
- Interventions
- Radiation: Intensity modulated total marrow irradiation
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 38
- Registration Number
- NCT06802315
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
Epidemiology of Infection in Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-01-28
- Target Recruit Count
- 100
- Registration Number
- NCT06797648
- Locations
- 🇮🇹
Fondazione Policlinico Universitario A. Gemelli Irccs, Uoc Ematologia, Rome, Italy
Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia(AML)
- Interventions
- Biological: RD-IIT-001Drug: CD84-CART
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 18
- Registration Number
- NCT06786299
- Locations
- 🇨🇳
No. 79, Qingchun Road, Hangzhou City, Zhejiang Province., Hangzhou, Zhejiang, China
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Interventions
- Drug: Anti-FLT3 CAR-T cells
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Hemogenyx Pharmaceuticals LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06786533
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States